Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 27Gastrointestinal 6Thoracic 5Breast 4Sarcoma 2Head & Neck 2Genitourinary 2Other solid neoplasm 1Dermatologic 1CNS 1

Conditions

Carcinoma, Renal Cell 77Kidney Neoplasms 23Prostatic Neoplasms 22Neoplasm Metastasis 13Colorectal Neoplasms 10Neoplasms 8Melanoma 7Carcinoma, Transitional Cell 6Breast Neoplasms 6Urinary Bladder Neoplasms 5Stomach Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Myeloproliferative Disorders 2Multiple Myeloma 2Hereditary leiomyomatosis and renal cell cancer 2Hematologic Neoplasms 2Financial Stress 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2

Interventions

pembrolizumab 18Nivolumab 6Radiotherapy 5Paclitaxel 5Trastuzumab 4Specimen Handling 4Ipilimumab 4tisotumab vedotin 3temsirolimus 3olaparib 3lenvatinib 3X-Rays 3Taxes 3Surveys and Questionnaires 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Biopsy 3zanidatamab 2spartalizumab 2sargramostim 2rucaparib 2palbociclib 2fludarabine 2epacadostat 2enzalutamide 2durvalumab 2cabozantinib 2atezolizumab 2aflibercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Bevacizumab × Genitourinary × Clear all
NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡